Osteogenesis Imperfecta Pipeline Summary

DelveInsight’s, “Osteogenesis Imperfecta - Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Osteogenesis Imperfecta pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteogenesis Imperfecta: Understanding

Osteogenesis Imperfecta: Overview

Osteogenesis imperfecta (OI), also known as brittle bone disease, is a genetic connective tissue disorder caused by abnormalities in the production or processing of type I collagen. It is primarily characterized by bone fragility, recurrent fractures, and reduced bone density, with additional manifestations including blue sclerae, dentinogenesis imperfecta, short stature, and progressive hearing loss. Cardiovascular complications such as valvular insufficiency and aortic root dilation may also occur, while milder features can include joint laxity, easy bruising, hernias, and excessive sweating. Clinical severity ranges from mild, minimally symptomatic disease to severe forms presenting early in life with multiple fractures, skeletal deformities, fragile cranial bones, and compromised ribs, which may result in substantial perinatal morbidity and mortality.

Osteogenesis imperfecta (OI) is a rare genetic disorder primarily associated with mutations in COL1A1 and COL1A2, which encode type I collagen, although advances in molecular genetics have identified several additional disease-associated genes, contributing to its diverse clinical presentations and inheritance patterns. The International Society of Skeletal Dysplasias classifies OI according to genetic and inheritance characteristics, supporting a genotype-based approach to diagnosis and management. Type I (nondeforming OI) is generally autosomal dominant and associated with COL1A1 or COL1A2 mutations, while an X-linked form is linked to PLS3. Type II (perinatal OI) may follow autosomal dominant or recessive inheritance and is associated with mutations in COL1A1, COL1A2, CRTAP, LEPRE1, PPIB, and BMP1. Type III (progressively deforming OI) can also exhibit either dominant or recessive inheritance and involves genes including COL1A1, COL1A2, CRTAP, LEPRE1, PPIB, FKBP10, SERPINH1, SERPINF1, and WNT1. Type IV (moderate OI) may be inherited through either pattern and is associated with mutations in COL1A1, COL1A2, CRTAP, FKBP10, SP7, SERPINF1, WNT1, and TMEM38B. Type V, characterized by interosseous membrane calcification or hypertrophic callus formation, typically follows autosomal dominant inheritance and is caused by mutations in IFITM5.

Type I collagen, the major structural protein of bone, skin, and tendons, is composed of two pro-alpha-1 chains and one pro-alpha-2 chain that form a rigid triple-helix structure. Each chain contains amino- and carboxyl-terminal pro-peptides surrounding a central region rich in repeating glycine residues, which are essential for proper triple-helix formation. Osteogenesis imperfecta primarily results from quantitative or qualitative abnormalities in type I collagen, with inheritance occurring through autosomal dominant, autosomal recessive, or de novo mechanisms. Autosomal dominant forms generally arise from direct defects in collagen genes, whereas recessive forms often involve mutations in proteins responsible for collagen processing, post-translational modification, or triple-helix assembly. Mutations that reduce normal collagen production, such as frameshift variants, can lead to collagen deficiency, while substitutions or deletions involving glycine can produce structurally abnormal collagen with impaired function. The severity of disease varies according to the nature and location of the mutation, with defects affecting the carboxyl-terminal region generally associated with more severe skeletal manifestations. Additional mutations involving components of the collagen hydroxylation and processing machinery can cause recessive forms of OI, further contributing to the genetic and clinical heterogeneity of the disorder.

The diagnosis of osteogenesis imperfecta (OI) is based on a comprehensive assessment of clinical presentation, family history, bone mineral density, biochemical parameters, and characteristic radiographic findings, while non-accidental trauma should be considered and excluded in patients presenting with multiple fractures. Bone fragility and recurrent fractures are the predominant clinical features, often accompanied by blue sclerae, dentinogenesis imperfecta, hearing loss, ligamentous laxity, joint hypermobility, short stature, and easy bruising, with clinical severity varying across OI subtypes. Recurrent fractures may lead to skeletal deformities, while healing is generally normal, although hypertrophic callus formation can occasionally occur. Routine laboratory findings are typically unremarkable, and no single diagnostic test can confirm all forms of OI because of its substantial genetic heterogeneity. Plain radiography may reveal features such as wormian bones, basilar invagination, kyphoscoliosis, osteoporosis, cortical thinning, skeletal deformities, hypertrophic callus, and pseudarthrosis, while prenatal ultrasound can identify skeletal abnormalities in severe forms. CT may provide additional assessment of cranial, skeletal, and auditory abnormalities, whereas MRI is particularly useful for evaluating basilar invagination. In diagnostically uncertain cases, specialized testing, including type I collagen analysis using fibroblast cultures or tissue biopsy, may support confirmation, with histological examination typically demonstrating reduced cortical thickness, decreased cancellous bone volume, and increased bone remodeling.

Management of osteogenesis imperfecta (OI) is individualized according to age, disease severity, fracture burden, and functional status, with treatment focused on preventing fractures, maintaining mobility, correcting skeletal deformities, and improving quality of life. Mild disease is generally managed with fracture care and avoidance of high-impact or contact activities, whereas moderate to severe disease may require multidisciplinary rehabilitation and orthopedic interventions for fractures, scoliosis, and long-bone deformities. Bisphosphonates, including pamidronate and alendronate, can reduce bone resorption, improve bone mineral density, and decrease fracture risk, while other approaches such as calcium, vitamin supplementation, and hormonal therapies have shown limited or inconsistent benefits. Investigational strategies include gene and cell therapies targeting collagen defects, sclerostin inhibition, denosumab, teriparatide, and TGF-?–targeted therapies, although these approaches remain under clinical investigation. Orthopedic management includes fracture treatment, physical rehabilitation, orthotic devices, walking aids, and wheelchairs, with osteotomy and intramedullary rodding used to correct or prevent progressive long-bone deformities in patients with recurrent fractures. Spinal abnormalities, including scoliosis and basilar invagination, also require ongoing surveillance and appropriate intervention, with the overall approach tailored to skeletal maturity and individual disease severity.

"Osteogenesis Imperfecta- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteogenesis Imperfecta pipeline landscape is provided which includes the disease overview and Osteogenesis Imperfecta treatment guidelines. The assessment part of the report embraces, in depth Osteogenesis Imperfecta commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteogenesis Imperfecta collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Osteogenesis Imperfecta R&D. The therapies under development are focused on novel approaches to treat/improve Osteogenesis Imperfecta.

Osteogenesis Imperfecta Emerging Drugs Chapters

This segment of the Osteogenesis Imperfecta report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteogenesis Imperfecta Emerging Drugs

Setrusumab: Mereo BioPharma / Ultragenyx Pharmaceutical

Setrusumab is a fully human monoclonal antibody that inhibits sclerostin, a key negative regulator of bone formation. By blocking sclerostin activity, setrusumab is designed to stimulate new bone formation, enhance bone mineral density, and improve bone strength in patients with osteogenesis imperfecta (OI). Preclinical studies in OI mouse models demonstrated that anti-sclerostin antibodies increased bone formation, restored bone mass toward normal levels, and improved resistance to fracture. Currently, the therapy is in Phase III stage of it’s development for the treatment Osteogenesis Imperfecta (OI).

AGA2115: Angitia Biopharmaceuticals

AGA2115 is a first-in-class investigational drug candidate discovered by Angitia for the treatment of osteogenesis imperfecta (OI). Preclinical studies in disease models demonstrated that AGA2115 produced robust effects on restoring bone mass and strength, improving overall bone quality, and reducing the incidence of skeletal fractures. These findings suggest that AGA2115 may have therapeutic potential in addressing the underlying skeletal abnormalities associated with OI and improving bone integrity and resilience. According to company’s pipeline, the therapy is in Phase II stage of it’s development for the treatment Osteogenesis Imperfecta (OI).

Further product details are provided in the report……..

Osteogenesis Imperfecta: Therapeutic Assessment

This segment of the report provides insights about the different Osteogenesis Imperfecta drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Osteogenesis Imperfecta
• There are approx. 8+ key companies which are developing the therapies for Osteogenesis Imperfecta. The companies which have their Osteogenesis Imperfecta drug candidates in the most advanced stage, i.e. Phase III include, Ultragenyx Pharmaceutical.
• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Osteogenesis Imperfecta pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteogenesis Imperfecta: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Osteogenesis Imperfecta therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteogenesis Imperfecta drugs.

Osteogenesis Imperfecta Report Insights

• Osteogenesis Imperfecta Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteogenesis Imperfecta Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteogenesis Imperfecta drugs?
• How many Osteogenesis Imperfecta drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteogenesis Imperfecta?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteogenesis Imperfecta therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteogenesis Imperfecta and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mereo BioPharma
• Ultragenyx Pharmaceutical
• Amgen
• UCB
• Angitiva Biopharmaceuticals
• Castle Creek Biosciences

Key Products

• Setrusumab
• Romosozumab
• AGA2115
• CCB-001